Cellectar Biosciences (NASDAQ:CLRB) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectar Biosciences (NASDAQ:CLRBGet Rating) in a research note released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on CLRB. Oppenheimer lowered their price target on shares of Cellectar Biosciences from $47.00 to $12.00 in a report on Friday, November 4th. HC Wainwright upped their target price on shares of Cellectar Biosciences from $3.00 to $4.00 and gave the stock a buy rating in a report on Friday, November 4th. Finally, Maxim Group lowered their target price on shares of Cellectar Biosciences to $7.00 in a report on Tuesday, November 15th.

Cellectar Biosciences Price Performance

Shares of Cellectar Biosciences stock opened at $1.88 on Monday. The firm has a market capitalization of $17.65 million, a PE ratio of -0.42 and a beta of 1.19. The company’s fifty day moving average price is $2.59 and its two-hundred day moving average price is $3.87. Cellectar Biosciences has a 52-week low of $1.75 and a 52-week high of $7.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLRB. AIGH Capital Management LLC lifted its position in Cellectar Biosciences by 104.9% during the 1st quarter. AIGH Capital Management LLC now owns 1,837,046 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 940,456 shares in the last quarter. Worth Venture Partners LLC lifted its position in Cellectar Biosciences by 122.8% during the 1st quarter. Worth Venture Partners LLC now owns 458,245 shares of the biopharmaceutical company’s stock worth $315,000 after buying an additional 252,570 shares in the last quarter. Renaissance Technologies LLC lifted its position in Cellectar Biosciences by 31.3% during the 2nd quarter. Renaissance Technologies LLC now owns 166,500 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 39,700 shares in the last quarter. 1900 Wealth Management LLC acquired a new position in Cellectar Biosciences during the 3rd quarter worth about $40,000. Finally, State Street Corp lifted its position in Cellectar Biosciences by 4.5% during the 2nd quarter. State Street Corp now owns 157,146 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 6,800 shares in the last quarter.

About Cellectar Biosciences

(Get Rating)

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM.

Further Reading

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.